Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 7795273 Pyrazolo[1,5-a]pyridine-3-carboxylic acids as EphB and VEGFR2 kinase inhibitors

Patent 7795273 was granted and assigned to Novartis on September, 2010 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Current Assignee

Novartis

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

77952730

Patent Inventor Names

Pascal Furet0

Patricia Imbach0

Philipp Holzer0

Date of Patent

September 14, 2010

Patent Application Number

120962600

Date Filed

December 6, 2006

Patent Citations Received

‌

US Patent 11851434 Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors

‌

US Patent 11998545 Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors

‌

US Patent 11964988 Fused heterocyclic compounds as RET kinase inhibitors

Patent Primary Examiner

‌

D. Margaret Seaman

Patent abstract

The invention relates to novel pyrazolo[1,5-a]pyridine-3-carboxylic acid compounds of the formula

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 7795273 Pyrazolo[1,5-a]pyridine-3-carboxylic acids as EphB and VEGFR2 kinase inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API